Selecting which data to analyse A rather more subtle problem that can occur in any study is the selection of which data to analyse. Errors may occur when analyses are carried out as a direct result of having seen the data. In a comparison of several groups of subjects it is not valid to select those groups with the highest and lowest values and apply the usual significance test to the means purely on that basis, because the null hypothesis of no difference is inappropriate when the largest difference is being examined. More generally, selection of comparisons to test because they "look interesting" will in the long run result in more than the nominal (say 5%) proportion of falsely positive results.
A second form of selection is to analyse only a subset of the subjects on the basis of their results. In a recent study 30 patients with idiopathic hypercalciuria were given a dietary supplement of unprocessed bran.1' Only 22 patients "achieved a reduction in urinary calcium," and only these 22 patients were analysed. No data were provided on the other eight subjects, so we can not tell whether they really were a different group or just one end of a distribution of differing responses to the bran, which seems more likely. This procedure is completely unacceptable without justification-anyone can show significant results by analysing only those subjects with the greatest response.
The basic principle is to analyse according to the original hypothesis and experimental design. Other results that look interesting are pointers for further research.
Summary
It is of no value collecting good data if the analysis is inadequate or invalid. The results obtained may then be worthless, or at best they wiJl fail to realise the true potential of the data. Either way, the value of the whole experiment is diminished to a point where the ethics of the investigation must be called into question. to another remains at best uncertain (one well-known example is that penicillin is lethal for guinea pigs at low doses). Secondly, there may be no animal species suitable for the studies required -when, for example, the main metabolites of a drug in man fail to appear in any of the animal species normally used for toxicity tests. In such cases the potential benefit of the drug to the patient has to be the guiding principle.
Risk/benefit balance
More recognition by the drug-regulatory agencies of the need to balance risks against benefits is, indeed, one of the priorities agreed by all those to whom I spoke. Typically, Dr Janssen (President, Janssen Pharmaceuticals) put the point most forcibly. "The first step," he claimed, "is simply to abolish regulations for drugs for life-taking diseases. Clearly some debate will be needed on the definition of these diseases: but that would be the start of a more sophisticated system of drug regulation." At the other end of the spectrum, he would expect very close examination of new drugs for common, non-life-threatening disorders. "The need for any more minor tranquillisers is debatable, to say the least," he added. "This is an example of a field in which I should tend to be rather tough and demanding and probably even insist on some proof of improved efficacy."
indication then a new addition to that list must be given a very rigorous dusting down before it is put into the market place." It might be unreasonable to expect it to show definite advantages, he conceded; but the point was that doctors would already know a great deal about the 20 existing drugs. No one could know that a 21st drug would not have to be taken off the market within two or three years because of some unacceptable adverse reaction.
Such a change in policy-making regulations more stringent for new entries to categories already well supplied-would, thought Dr Dunne, have the beneficial side effect of perhaps pushing the drug companies into fresh areas of innovation. Dr Smith (Director of Clinical Research and Development with I-foffmann La Roche, Basle) took a somewhat different attitude. He thought it was illogical to withdraw ultimate responsibility from the company for deciding whether to launch a drug and to shift that responsibility on to government agencies, who often took divergent decisions. The illogicality was even more apparent now that legal liability was being put on to manufacturers." The professionalism in the industry is at least as good as that outside," said Dr Smith. "Often the experience of agency staff, who have not seen all the problems and their solutions in the whole period of development, is questionable-if one judges them on the comments they make to us."
Simpler innovation
Certainly in the case of drugs for rare diseases and some classes of anticancer drugs the consensus was plain: innovation must be made simpler if research was to continue. "Take a drug used in cancer treatment," said Dr Smith. "We are hoping shortly to get a UK licence for a drug of this type: but even on the most optimistic projections we cannot expect to make more than 1500 000 profit in the next decade-and much more probably we shall make no money at all. At some stage the senior management is going to tell the research and development staff that it wants better results than that on investment which averages £30 million for each new drug." Some way had to be found to simplify the development programme for drugs of this kind if the supply was not to dry up because for each drug launched five or more failed during development.
A second possible area for action would be extension of the effective patent life of new drugs. Extending the period of patent-protected profitability should encourage companies to develop drugs with smaller potential markets; and companies would feel under less pressure to innovate or reformulate or redevelop new drugs to replace their market leaders as they came to the end of their period of patent protection.
"Such a mechanism could be very attractive," said Dr Dunne, "but somehow or other the voice of the third world would need to be accommodated. If drugs of clear value to poor countries are going to be very expensive for longer periods that would raise a moral issue-for most of the profits would be directed into research areas of little direct value to the community concerned. Dr Dunne thought that more attention should be given to the need for new drugs in the third world. There were two conflicting priorities. Some way had to be found to supply essential drugs as cheaply as possible; but at the same time companies had to be persuaded that the investment required for innovations was likely to be recoverable. "A research based drug industry without profits does no research," said Dr Dunne, "but I think the industry would agree that among the least developed countries the need is for today rather than for tomorrow."
The most important change required, however, is in attitudes of the drug-regulatory agencies. Introduced as they were to prevent epidemics of drug-induced damage, their approach has inevitably been cautious. The 1970s were characterised by consumer groups demanding that drugs should be safe, and the public were persuaded that the goal of safety was obtainable provided testing was sufficiently rigorous and thorough. Now, as the climate of opinion has changed and the public has come to understand that effective medicines carry some (albeit small) risk, the drug regulatory agencies have a chance to loosen the screws and positively to facilitate the development of new drugs. Whether or not they do so will depend partly on the beliefs of the political directors of those agencies and partly on the attitudes of their scientific advisers and full-time staff.
So long as some of the individuals in control of national drug-testing policies continue to adopt anti-industry postures there will be little chance of worthwhile reforms. For a generation or more the populist stance has been to attack the pharmaceutical industry as inherently piratical: the public has been told repeatedly that drug companies will-unless restrained-make outrageous profits out of medicines of dubious efficacy and safety.
The restraints, checks, and precautions devised to protect the public against these-at least partly illusory-dangers have now to be dismantled if the industry is not to be stifled. Pressure for reform will have to come from sources both inside the industry and outside it. In particular, the industry's drug toxicologists ought to be able to propose ways to simplify and streamline the present rigid patterns of preclinical toxicity testing, and a working group set up by the IFPMA and headed by Professor Lars Werk6 is looking at that possibility. Several other organisations are looking at ways of avoiding unnecessary repetition when drugs licensed for one country are introduced into another. In the end, however, the regulatory agencies will respond to changes in the climate of professional and public opinion. If doctors and their patients are to continue to be supplied with new, effective drugs they will need to press for a simplified system of regulation.
Contemporary Themes
Promoting the use of seat belts programmes and yet no controlled study has been performed in Britain to assess whether "seat belt wearing rates can be significantly raised by education." As a result of its concern for the prevention of death and injury from road accidents, Wessex Regional Health Authority mounted a research project to test this hypothesis.
Method
The study was carried out between November 1979 and March 1980 in two local authority districts, Winchester and Salisbury, with similar demographic features. Winchester was designated the "target" population and received educational programmes promoting the use of seat belts. Salisbury acted as the "control" population whereby any unrelated fluctuations in the rate of wearing seat belts could be monitored.
Measurement of this rate in the two towns was based on observation of front seat occupants of cars and light vans entering two matched
